The first long-acting option to protect Women from HIV, proven to reduce women’s Hiv Risk, has been recommended for use by the World Health Organization (WHO). For nearly two decades, researchers from the School of Pharmacy at Queen’s University Belfast have been supporting development of a new drug-releasing vaginal ring to protect women from infection with the human immunodeficiency virus (HIV). It will be the first long-acting option that women can use to reduce their risk of HIV transmission representing an important milestone in prevention technologies. The monthly dapivirine ring, developed by the International Partnership for Microbicides (IPM) with critical research and development

Reducing HIV risk for women as seen on The Hippocratic Post.